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A major impetus to initiating the Human Genome
Project was the belief that information encoded in
the human genome would ‘‘accelerate progress in
understanding disease pathogenesis and in developing
new approaches to diagnosis, treatment, and preven-
tion in many areas of medicine’’. Alopecia areata (AA) is
a notable example of how understanding the genetic
basis of a disease can have an impact on the care of
patients in a relatively short time. Our first genome-
wide association study in AA identified an initial set
of common variants that increase risk of AA, some of
which are shared with other autoimmune diseases.
Thus, there has already been rapid progress in the
translation of this information into new therapeutic
strategies for patients, as drugs are already on the
market for some of these disorders that can now be
tested in AA. Informed by the progress achieved with
genetic studies for mechanistically aligned auto-
immune diseases, we are poised to carry this work
forward and interrogate the underlying disease
mechanisms in AA. Importantly, future genetic studies
aimed at identifying additional susceptibility genes will
further establish the foundation for the application of
precision medicine in the care of AA patients.
Journal of Investigative Dermatology Symposium Proceedings (2013) 16,
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INTRODUCTION
Alopecia areata (AA) is an disease that targets hair follicles in
the skin, causing disfiguring hair loss that is histologically
marked by an accumulation of infiltrating immune cells
around the affected hair follicles. AA is the most prevalent
autoimmune disease in the United States) Cooper et al., 2009;
AARDA, 2011), affecting both men and women of all ages
(Gip et al., 1969; van der Steen et al., 1992; McMichael et al.,
2007). With a lifetime risk of 1.7% (Safavi et al., 1995), AA
affects more individuals than most other autoimmune diseases
combined, and yet despite its prevalence, there is an
enormous unmet medical need (Delamere et al., 2008) that
arose primarily from the scarcity of information about its
underlying pathogenesis.
Human genetic studies have proven to be an efficient
method for gaining critical insight into disease mechanisms
in general, and have provided profound insights into the
pathogenesis in AA. Initial evidence supporting a genetic basis
for AA was obtained from multiple lines of research, including
increased risk of disease in first-degree relatives (van der Steen
et al., 1992; McDonagh and Tazi-Ahnini, 2002), twin studies
(Jackow et al., 1998; Rodriguez et al., 2010), and studies in
animal models (Sundberg et al., 2004). The earliest genetic
studies performed in AA were candidate–gene association
studies, which investigated one or a few genes chosen on the
basis of a prior hypothesis about function, and typically based
on the involvement of the gene in other clinically similar
autoimmune diseases. Although these initial genetic studies
tended to be limited in terms of sample size and by definition,
biased by choices of candidate genes, they nonetheless
demonstrated important associations with genes within the
HLA complex: HLA-DQB1, HLA-DRB1, HLA-A, HLA-B, HLA-
C, NOTCH4, and MICA, as well as genes outside of the HLA:
PTPN22 and AIRE (reviewed in Gilhar et al., 2007).
In contrast to candidate gene methods, genome-wide
studies survey the entire genome for evidence of genetic
contributions to disease without the a priori exclusion of any
loci. Thus, these are particularly powerful methods for resol-
ving disease mechanisms that are largely unknown. Currently,
genome-wide methods can be categorized into marker- or
sequencing-based methods. Marker-based methods, such as
linkage analysis and genome-wide association study (GWAS),
rely upon typing genetic markers to identify genomic regions
with marker alleles whose distributions are consistent with the
presence of a proximal risk variant. Genome-wide sequen-
cing-based methods have only recently become feasible, with
the emergence of next-generation sequencing techno-
logies (Shendure and Ji, 2008; Feero et al., 2010). These
strategies generate whole-genome or whole-exome data,
obviating the assumption that a risk variant is in physical
proximity to a genetic marker. Catalogs of all variants
present in an individual’s genome or exome are created
and then filtered or prioritized in a number of ways,
depending on the particular study design (reviewed in Cirulli
and Goldstein, 2010), allowing for the direct detection of a
disease variant.
Each of these strategies may be performed in either
cohorts of families or unrelated individuals, and the type of
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cohort will determine the analytic strategy. For example,
marker-based strategies in family cohorts will require linkage
analysis or family-based association tests, whereas cohorts of
unrelated individuals are used for GWAS. These two marker-
based approaches are complementary to one another. Differ-
ent sets of assumptions underlie each method, such that
linkage methods are more likely to detect rare disease
alleles, whereas GWAS are more likely to detect common
risk alleles.
Linkage methods identify genetic markers that cosegregate
with disease in families and have the greatest power for
detection of disease alleles that are rare in the population and
have a strong effect on disease expression. Linkage evidence is
generally robust to biases that can influence association
studies, such as population stratification. Genomic regions
identified in linkage studies tend to be quite large, and so
generally preclude the immediate identification of specific
genes, but rather serve as a starting point for further positional
mapping that historically has involved sequencing of candi-
date genes within the linkage interval. With the recent
development of next-generation sequencing, linkage informa-
tion can be incorporated into a filtering strategy, prioritizing
variants from whole-exome sequencing or targeted resequen-
cing experiments.
GWAS compare allele frequencies for large numbers of
genetic markers across groups of unrelated cases and controls,
and are best suited for detecting disease alleles whose
frequencies are within the same range as those of the tagSNPs
(single-nucleotide polymorphisms) that are present on (or
imputed from) commercial genotyping arrays, and these tend
to be common in the population. Power to detect an
association is reduced when there is a large difference in
allele frequency between the marker and the disease allele,
even if these are in perfect linkage disequilibrium (Gordon and
Finch, 2005). Therefore, a rare disease allele (Po0.01)
may not demonstrate evidence for association. Furthermore,
disease alleles that are common in the population are not
likely to have strong phenotypic effects. GWAS tend to be
more sensitive to confounding from ancestry, although there
are analytic methods to test and correct for such biases.
Finally, associated regions identified by GWAS tend to be
much smaller than linkage regions. Therefore, this method has
the potential to identify individual genes or small clusters of
functionally related genes.
Thus, linkage methods are best for identifying rare disease
alleles with strong effects, whereas association methods are
well-suited for identifying common disease alleles with weak
effects. Importantly, recent empirical evidence, which is
augmented by theoretical arguments, suggests that the genetic
architecture of common diseases contains niches for both rare
and common alleles (Cohen et al., 2004; Fearnhead et al.,
2004; Cohen et al., 2006; Ahituv et al., 2007; Gorlov et al.,
2008; Ji et al., 2008; Frazer et al., 2009; Manolio et al., 2009;
Orru et al., 2009; Emison et al., 2010; Wang et al., 2010;
Zaghloul et al., 2010; Raychaudhuri et al., 2011; Jordan et al.,
2012), such that dissection of a complex disease should
involve both linkage and GWAS to fully enumerate the
underlying architecture.
UNBIASED GENETIC STUDIES IN AA
To date, genome-wide studies in AA have almost exclusively
used marker-based methods and include two GWAS, and a
genome-wide linkage analysis (Martinez-Mir et al., 2007;
Petukhova et al., 2010; Forstbauer et al., 2012). More
recently, a whole-exome sequencing study was performed in
a small sample of six unrelated AA patients, but was
underpowered to detect meaningful associations (Lee et al.,
2013). The results from the marker-based studies confirm
that there is unequivocally a genetic basis to AA, and
indicate that the genetic architecture is polygenic, composed
of both common and rare risk alleles, and consistent with
emerging evidence in other autoimmune diseases (Trynka
et al., 2011; Rivas et al., 2011; Jordan et al., 2012; Diogo
et al., 2013).
We first conducted a genome-wide linkage study in AA and
identified several genomic regions that cosegregated in
families (Martinez-Mir et al., 2007). Microsatellite markers
were used to genotype a cohort of 20 US and Israeli families.
We demonstrated strong evidence for linkage on chromosome
6q23.2 (logarithm of the odds (LOD)¼ 3.6) and suggestive
evidence in several additional regions. Fine mapping with
microsatellite markers was then performed in an expanded
cohort of 38 families for six regions. This analysis upheld
evidence on chromosomes 6q23.3–q24.1 (LOD¼2.89) and
16q12.2 (LOD¼ 3.12), and strengthened evidence on
chromosome 18p11.31–p11.21 (LOD¼ 3.93). This study
provided robust evidence for genetic contributions to AA,
and suggests that the genetic architecture contains rare disease
variants. Because the linkage study identified at least four
distinct regions in the genome, it supports the notion that AA is
a complex disease, with contributions to risk from several
genes.
We next embarked upon the first GWAS for AA, comparing
allele frequencies between a group of 1,054 unrelated AA
patients from the National Alopecia Areata Registry and 3,278
unrelated controls (Petukhova et al., 2010). Our study
identified 139 genotyped and 175 imputed single-nucleotide
polymorphisms (SNPs) with statistically significant association
to AA (Po5 10 7), which primarily cluster in eight regions
of the genome, implicating genes of the immune system, as
well as genes that are unique to the hair follicle: (1) 2q33.2
containing cytotoxic T-lymphocyte-associated protein 4
(CTLA4); (2) 4q27 containing the IL-2/IL-21 locus; (3)
6p21.32 containing the HLA class II region; (4) 6q25.1,
which harbors the ULBP gene cluster; (5) 9q31.1 containing
syntaxin 17 (STX17); (6) 10p15.1 containing IL-2RA; (7) 11q13
containing peroxiredoxin 5 (PRDX5); and (8) 12q13
containing ikaros family zinc-finger 4 (IKZF4; Eos) and v-erb-
b2 avian erythroblastic leukemia viral oncogene homolog 3
(ERBB3). In addition, an imputed SNP in 18p11.21 exceeded
our threshold for statistical significance and is located
downstream of PTPN2. The biological and therapeutic
implications of these candidate susceptibility genes and
pathways have been reviewed elsewhere (Petukhova et al.,
2011), although very recently a novel role for STX17 has come
to light. Previously, the function of STX17 was largely
unknown. However, several studies now show that STX17 is
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a SNARE protein with a specific role in autophagy (Itakura
et al., 2012; Hamasaki et al., 2013; Itakura and Mizushima,
2013). Furthermore, a mechanistic link between auto-
phagocytosis and pigmentation was uncovered when it was
shown that the biogenesis of melanosomes, pigment-
producing lysosome-related organelles, is regulated in part
by proteins that are also involved in autophagosome bio-
synthesis (Ho and Ganesan, 2011). Furthermore, as STX17 is a
major determinant of hair follicle pigmentation in horses
(Rosengren Pielberg et al., 2008; Curik et al., 2013), and in
humans is expressed in the hair shaft cortex (Petukhova et al.,
2010), this raises the interesting possibility that STX17 may
offer insight into the long-postulated role of melanocytes and
pigmented hairs in AA (Messenger and Bleehen, 1984; Tobin
et al., 1990; Tobin and Bystryn, 1996).
Replication of statistical associations remains the gold
standard for evaluating the validity of GWAS findings
(McCarthy et al., 2008). Importantly, each of the GWAS
regions identified in AA has been confirmed through
independent replication studies or previous candidate gene
studies (Petukhova et al., 2010; John et al., 2011; Jagielska
et al., 2012). More recently, a second GWAS was performed
for AA in which a pooled genotyping strategy was used to
analyze approximately 700 cases and 700 controls (Forstbauer
et al., 2012). Outside of the HLA, a new locus, containing
spermatogenesis-associated 5 (SPATA5), exceeded statistical
significance and was replicated in an independent sample.
This region harbors several SNPs that had achieved nominal
significance in the first GWAS (Po104) (Petukhova et al.,
2010). This study highlights the importance of conducting
multiple GWAS to identify new loci.
Importantly, the ‘‘common cause’’ genes that were identi-
fied in our first GWAS helped to align AA within the broader
context of susceptibility to autoimmune disease, and revealed
previously unsuspected relationships (Figure 1). For example,
our GWAS identified a number of risk loci in common with
other forms of autoimmunity, such as type 1 diabetes,
rheumatoid arthritis, and celiac disease, in particular, CTLA4,
IL-2/IL-2RA, IL-21, and genes critical to T-regulatory
maintenance. The gene cluster containing NKG2D ligands
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Figure 1. Relationships among a set of 12 autoimmune diseases inferred from genome-wide association study (GWAS) data. As of March 2013, 107 GWAS
have been published for 12 autoimmune diseases, implicating 428 genomic regions (http: //www.genome.gov/gwastudies). A network plot is created to infer
disease relationships from GWAS evidence (Cytoscape) (Shannon et al., 2003). Edges (associations) connect genomic regions (blue nodes) to each disease
(white nodes) for which there is a statistically significant association. Distance between disease nodes reflects the extent of common causes, such that there
are more shared risk loci among diseases that are closer together in the plot. Loci that are unique to a disease are located toward the outside of the network.
Edges for loci associated with AA (opaque blue nodes) are in red, highlighting relationships revealed by GWAS in AA. Genes located within AA–associated
regions are indicated in black. AA, alopecia areata; CD, Crohn’s disease; CeD, celiac disease; CTLA4, cytotoxic T-lymphocyte-associated protein 4; ERBB3,
erythroblastic leukemia viral oncogene homolog 3; IBD, inflammatory bowel disease; IKZF4, ikaros family zinc-finger 4; MS, multiple sclerosis; PRDX5,
peroxiredoxin 5; Ps, psoriasis; RA, rheumatoid arthritis; SLE, system lupus erythematosus; SS, systemic sclerosis; STX17, syntaxin 17; T1D, type 1 diabetes;
UC, ulcerative colitis; Vi, vitiligo.
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ULBP3/ULBP6 was implicated for the first time in our GWAS,
and further unites this set of autoimmune diseases, as NKG2D
has been implicated by genetic and/or immunological evi-
dence for each disease (Garg et al., 2001; Barahmani et al.,
2004; Caillat-Zucman, 2006; Ito et al., 2008; Petukhova et al.,
2010). Finally, several of the genes implicated by our GWAS
are targets for drugs that are in development or already
available to treat other autoimmune diseases. For example,
Abatacept is a form of recombinant CTLA4-Ig used in the
treatment of rheumatoid arthritis and currently in clinical
trials for the treatment of several other autoimmune diseases.
In addition, there is compelling preclinical data in AA
demonstrating that CTLA4-Ig prevents disease onset in the
C3H/HeJ mouse model of AA (Dhabhar and McEwen, 1999).
The findings from our first GWAS in AA provide initial clues
that are likely to transform the development of treatments for
this disease. Clinical trials using Abatacept are commencing in
2013, only 3 years since the identification of CTLA4 as a risk
gene in AA.
FROM BASEPAIRS TO BEDSIDE
The goal of any therapeutic strategy devised for treatment of
an autoimmune disease is modulation of an immune response.
The treatment should target the pathway(s) perturbed in
disease while abrogating effects on the myriad of immune
system functions that support the health of the patient.
Furthermore, because emerging evidence indicates that
patients with clinically similar disease may have different
underling physiological aberrations, optimally there should be
a range of treatment options available to treat across the
spectrum of perturbed pathways for any one disease (Melmed
and Targan, 2010; Virgin and Todd, 2011; Mirnezami et al.,
2012). This necessitates intricate knowledge of the perturbed
pathways, as well as the relationships these hold to other
processes within the immune system.
Clinical trials in other autoimmune diseases have demon-
strated that even when a drug is efficacious for a majority of
patients, it may fail to elicit a treatment response for an
unacceptably high number of patients. For example, the tumor
necrosis factor–specific mAb infliximab is approved for the
treatment of Crohn’s disease (CD), as well as rheumatoid
arthritis, and psoriasis. However, up to 30% of CD patients
gain no benefit from treatment (Steinman, 2010), and some
patients actually experience treatment-induced onset of a
second autoimmune disease, which sometimes can include
AA (Perez-Alvarez et al., 2013). Therefore, given the
complexity of disease and treatment responses, it is
imperative that an arsenal of therapeutic options is available
for any one disease. Finally, drug repositioning that is guided
by rationale derived from molecular evidence is more efficient
than by simply relying upon clinical similarities between
diseases (Dudley et al., 2011; Mathur and Dinakarpandian,
2011). For these reasons, it is crucial that we continue to
advance and refine genetic studies in AA, and expand the
number of risk genes.
The identification of new susceptibility loci for AA will help
to clarify the biological pathways that underlie disease and
provide rationale for future therapeutic strategies. Importantly,
it will also provide a foundation for ‘‘precision medicine’’.
One of the most important lessons emerging from genomic
‘big data’ is that clinically similar diseases can be composed of
molecularly distinct subtypes. This observation was first made
with gene expression data in breast cancer (Rouzier et al.,
2005), and has allowed for precision medicine in the
treatment of this disease, with particular genomic signatures
driving treatment decisions for the patient. GWAS data from
autoimmune diseases supports the existence of mechanistic
subtypes within some of these disorders as well (Virgin and
Todd, 2011). The ability to identify these subtypes from
genomic data (genotyping or sequencing of the genome or
transcriptome) requires larger sample sizes than have currently
been analyzed for AA, although future studies will allow the
same investigations in AA. Thus, it is critical that we follow the
paradigms being established in other autoimmune diseases by
expanding the size and scope of our genetic studies.
FUTURE DIRECTIONS
Our linkage studies provide strong evidence for the existence
of alleles cosegregating with disease, and also provide a
critical starting point for methods that utilize next-generation
sequencing technologies to generate whole-exome or whole-
genome sequence data. The integration of whole-exome/
genome sequencing data with linkage evidence is emerging
as a powerful new means to identify disease alleles, providing
an economical and efficient way to catalog all linkage-interval
variants, and a robust strategy for prioritizing the vast number
of novel variants revealed by whole-exome/genome sequen-
cing (Sobreira et al., 2010; Cabral et al., 2012). The ongoing
efforts of the National Alopecia Areata Registry have
substantially expanded our family cohort since the
completion of our first genome-wide linkage scan. In
addition, although our first linkage study utilized micro-
satellite markers, commercial genotyping arrays of SNPs
offer increased information content, which increases the
power to detect linkage (Amos et al., 2006). Moreover,
having both our family cohort and our GWAS cohort of
unrelated individuals genotyped on a common platform will
allow us to integrate the two data sets and better characterize
the genetic architecture of AA.
Importantly, emerging evidence from a number of complex
diseases suggests that both rare and common disease alleles
contribute to susceptibility and thus argues for pursuit of both
linkage and GWAS when the goal is to illuminate compre-
hensively the genetic architecture of a disorder. As an
illustrative example, GWAS have been tremendously success-
ful for identifying loci that contribute to inflammatory bowel
disease (IBD), with more than 160 loci demonstrating
statistically significant association (Jostins et al., 2012), and
yet paradoxically, one gene with strong functional evidence
for pathogenic involvement in the diseases escaped detection
by GWAS or meta-analysis, because it never exceeded the
threshold for statistical significance. X-box binding protein 1
was initially identified in a molecular screen for proteins that
bind to X-box elements, which are found in the promoters of
human major histocompatibility complex (MHC) genes. The
selective knockout of X-box binding protein 1 in mouse
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intestinal epithelium recapitulates many of the traits associated
with IBD in humans, including spontaneous intestinal inflam-
mations accompanied by lamina propria polymorphonuclear
infiltrates, crypt abscesses and frank ulcerations, and an
increase in intraepithelial lymphocyte numbers (Kaser et al.,
2008; Glimcher, 2010). Following phenotypic characteri-
zation of this mouse model, a candidate gene association
study was performed in a cohort of 1100 IBD cases and 1100
controls and identified an SNP with evidence for association
that exceeded a candidate gene threshold (P¼1.6 105),
but would have not exceeded a genome-wide significance
level in a GWAS (Kaser et al., 2008). Importantly, the region in
the genome that harbors X-box binding protein 1 was
previously implicated with nominal evidence for linkage in
three independent family-based studies (Hampe et al., 1999;
Barmada et al., 2004; Vermeire et al., 2004), and targeted
resequencing of the gene demonstrated a 3-fold increase of
rare SNPs in IBD patients relative to controls and iden-
tified five rare nonsynonomous variants that were not
seen in control patients (Kaser et al., 2008). Cumulatively,
this evidence suggests that pursuing linkage studies in combi-
nation with deep sequencing is a powerful approach that can
identify genes that contribute to common disease and can
escape detection with GWAS.
The trajectory for gene discoveries by GWAS in other
autoimmune diseases suggests that there are many more risk
alleles in AA that are common in the population and await
discovery from GWAS in larger cohorts. For example, before
the initial GWAS in CD, only a single locus had been
implicated by human genetic studies, NOD2, which was
identified by positional cloning with linkage analysis. The first
set of GWAS in CD each analyzed o1,000 patients and
identified approximately 10 causal loci, similar to the numbers
we are observing in AA. When meta-analyses began to be
performed across increasingly larger data sets, the number of
loci increased markedly, such that today, there are 160 bona
fide disease loci in CD (Jostins et al., 2012). This trajectory
has been remarkably reproducible across a number of auto-
immune diseases. In fact, the relationship between sample
size and genetic associations is powerfully illustrated by
assessing the single largest GWAS for each autoimmune
disease in the NIH database of GWAS (http://www.
genome.gov/gwastudies) and the number of loci identified
with statistically significant associations, as is shown in
Figure 2. Clearly, there is much more biological insight to
be gained by conducting additional GWAS in independent
AA cohorts and performing meta-analyses across studies,
thereby substantially increasing sample size.
The inaugural genome-wide studies in AA have demon-
strated success, both in providing new insight into the
pathology of this highly prevalent disease and in suggesting
new therapeutic strategies that leverage treatments currently
available for mechanistically aligned autoimmune diseases.
AA patients are at the forefront of realizing the initial promises
of the Human Genome Project. Continued momentum in
genetic studies for AA will help to refine our understanding of
disease mechanisms and importantly lay a foundation for
precision medicine in the treatment of AA.
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